- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Automatic Translation feature is available on CiNii Labs
- Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
-
- ITO SETSUKO
- Department of Pediatrics, Kyoto University
-
- MAYUMI MITSUFUMI
- Department of Pediatrics, Kyoto University
-
- ITO MASATOSHI
- Department of Pediatrics, Kyoto University
-
- MIKAWA HARUKI
- Department of Pediatrics, Kyoto University
Bibliographic Information
- Other Title
-
- 小児科領域における Sulbactam/Ampicillinの臨床的検討
Description
Sulbactam/Ampicillin (SBT/ABPC), a combination at a fixed ratio of ABPC and SBT which is an irreversible inhibitor of β-lactamase in a 2:1 ratio, was clinically evaluated for its efficacy and safety in 24 patients with ages from 5 month-old to 12 years old with bacterial infection. The results obtained are summarized as follows.<BR>1. A pharmacokinetic study following 30mg/kg SBT/ABPC administration by 30 minutes drip infusion or intravenous bolus injection showed that mean half-lives of SBT and ABPC were 48.9 minutes and 40.2 minutes, respectively, and mean urinary excretion rates of SBT and ABPC in the first 6 hours were 67.1% and 48.3%, respectively.<BR>2. SBT/ABPC was administered to 14 patients with bronchopneumonia, 4 patients with tonsillitis, a patient each with acute upper respiratory infection, with submandibular lymphadenitis, with phlegmon, with enterocolitis, with pyelonephritis and with crystitis at a daily dosage of 88.2-133.3 mg/kg, divided into 3 or 4, by intravenous bolus injection or by 30 minutes drip infusion. Clinical responses of the 24 patients were as follows: excellent: 17 patients, good: 7 patients. The efficacy rate was 100%.<BR>3. Neither clinical adverse reactions nor abnormal laboratory test values, except slight eosinophilia in a patient and an elevation of GOT, GPT in another were observed.<BR>4. MICs of SBT/ABPC against 7 strong β-lactamase producing strains isolated from some of the patients were as follows.<BR>MIC against a strain of Staphylococcus aureus was 3.13 μg/ml, MICs against 2 out of 5 strains of Branhamella catarrhalis were 0.10μg/ml and those of the remaining 3 strains were 0.20 μg/ml. MIC against a strain of Haemophilus parainfluenzae was 3.13 μg/ml.<BR>5. These data described above show that SBT/ABPC has excellent bactericidal capacity against β-lactamase producing bacteria as well as β-lactamase non-producing Gram-positive and negative bacteria and suggest that SBT/ABPC is a very useful antibiotic for pediatric patients.
Journal
-
- The Japanese Journal of Antibiotics
-
The Japanese Journal of Antibiotics 42 (3), 675-685, 1989
Japan Antibiotics Research Association
